nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—SRMS—knee—psoriatic arthritis	0.0464	0.154	CbGeAlD
Bosutinib—BMP2K—synovial membrane of synovial joint—psoriatic arthritis	0.0154	0.0511	CbGeAlD
Bosutinib—BMX—skin of body—psoriatic arthritis	0.00526	0.0175	CbGeAlD
Bosutinib—CDK2—skin of body—psoriatic arthritis	0.00479	0.0159	CbGeAlD
Bosutinib—TLK1—tendon—psoriatic arthritis	0.00433	0.0144	CbGeAlD
Bosutinib—PRKCQ—tendon—psoriatic arthritis	0.00427	0.0142	CbGeAlD
Bosutinib—PLK2—skin of body—psoriatic arthritis	0.00422	0.014	CbGeAlD
Bosutinib—CLK3—tendon—psoriatic arthritis	0.004	0.0133	CbGeAlD
Bosutinib—STK24—skin of body—psoriatic arthritis	0.00394	0.0131	CbGeAlD
Bosutinib—PHKG1—tendon—psoriatic arthritis	0.00391	0.013	CbGeAlD
Bosutinib—EIF2AK1—tendon—psoriatic arthritis	0.00387	0.0129	CbGeAlD
Bosutinib—TYRO3—skin of body—psoriatic arthritis	0.00381	0.0127	CbGeAlD
Bosutinib—FES—tendon—psoriatic arthritis	0.00375	0.0125	CbGeAlD
Bosutinib—VRK2—tendon—psoriatic arthritis	0.00375	0.0125	CbGeAlD
Bosutinib—SYK—tendon—psoriatic arthritis	0.00368	0.0122	CbGeAlD
Bosutinib—TNIK—tendon—psoriatic arthritis	0.00368	0.0122	CbGeAlD
Bosutinib—CDK2—tendon—psoriatic arthritis	0.00364	0.0121	CbGeAlD
Bosutinib—STK26—tendon—psoriatic arthritis	0.00361	0.012	CbGeAlD
Bosutinib—CHEK2—tendon—psoriatic arthritis	0.00349	0.0116	CbGeAlD
Bosutinib—DMPK—tendon—psoriatic arthritis	0.00346	0.0115	CbGeAlD
Bosutinib—WEE1—tendon—psoriatic arthritis	0.00346	0.0115	CbGeAlD
Bosutinib—BMPR2—skin of body—psoriatic arthritis	0.00342	0.0113	CbGeAlD
Bosutinib—STK25—tendon—psoriatic arthritis	0.0033	0.011	CbGeAlD
Bosutinib—PLK2—tendon—psoriatic arthritis	0.00321	0.0107	CbGeAlD
Bosutinib—SIK3—tendon—psoriatic arthritis	0.00319	0.0106	CbGeAlD
Bosutinib—MAP2K1—skin of body—psoriatic arthritis	0.00317	0.0105	CbGeAlD
Bosutinib—STK35—skin of body—psoriatic arthritis	0.00317	0.0105	CbGeAlD
Bosutinib—CSK—skin of body—psoriatic arthritis	0.00315	0.0105	CbGeAlD
Bosutinib—CSNK1A1—skin of body—psoriatic arthritis	0.00313	0.0104	CbGeAlD
Bosutinib—CAMK1D—tendon—psoriatic arthritis	0.00303	0.0101	CbGeAlD
Bosutinib—STK24—tendon—psoriatic arthritis	0.003	0.00996	CbGeAlD
Bosutinib—CSNK1E—skin of body—psoriatic arthritis	0.0029	0.00965	CbGeAlD
Bosutinib—FER—tendon—psoriatic arthritis	0.0029	0.00964	CbGeAlD
Bosutinib—SIK1—skin of body—psoriatic arthritis	0.00286	0.00949	CbGeAlD
Bosutinib—MAP4K1—tendon—psoriatic arthritis	0.00284	0.00944	CbGeAlD
Bosutinib—BTK—tendon—psoriatic arthritis	0.00283	0.00939	CbGeAlD
Bosutinib—ERBB3—skin of body—psoriatic arthritis	0.0028	0.00931	CbGeAlD
Bosutinib—MAP2K2—skin of body—psoriatic arthritis	0.0028	0.00928	CbGeAlD
Bosutinib—MAP4K2—tendon—psoriatic arthritis	0.00275	0.00913	CbGeAlD
Bosutinib—PTK2—skin of body—psoriatic arthritis	0.00272	0.00903	CbGeAlD
Bosutinib—ERBB4—tendon—psoriatic arthritis	0.00271	0.00901	CbGeAlD
Bosutinib—STK3—tendon—psoriatic arthritis	0.00271	0.00901	CbGeAlD
Bosutinib—BMPR2—tendon—psoriatic arthritis	0.0026	0.00863	CbGeAlD
Bosutinib—AXL—skin of body—psoriatic arthritis	0.00259	0.0086	CbGeAlD
Bosutinib—STK36—tendon—psoriatic arthritis	0.00258	0.00857	CbGeAlD
Bosutinib—MERTK—tendon—psoriatic arthritis	0.00255	0.00847	CbGeAlD
Bosutinib—MAP4K4—tendon—psoriatic arthritis	0.0025	0.00831	CbGeAlD
Bosutinib—BCR—tendon—psoriatic arthritis	0.00248	0.00825	CbGeAlD
Bosutinib—MAP3K12—tendon—psoriatic arthritis	0.00247	0.00819	CbGeAlD
Bosutinib—FYN—skin of body—psoriatic arthritis	0.00242	0.00805	CbGeAlD
Bosutinib—STK35—tendon—psoriatic arthritis	0.00242	0.00803	CbGeAlD
Bosutinib—CSK—tendon—psoriatic arthritis	0.0024	0.00797	CbGeAlD
Bosutinib—CSNK1A1—tendon—psoriatic arthritis	0.00239	0.00792	CbGeAlD
Bosutinib—HCK—tendon—psoriatic arthritis	0.00237	0.00787	CbGeAlD
Bosutinib—CLK1—tendon—psoriatic arthritis	0.00237	0.00787	CbGeAlD
Bosutinib—MAP3K3—skin of body—psoriatic arthritis	0.00237	0.00786	CbGeAlD
Bosutinib—ABL2—tendon—psoriatic arthritis	0.00236	0.00782	CbGeAlD
Bosutinib—CAMK2G—tendon—psoriatic arthritis	0.00233	0.00773	CbGeAlD
Bosutinib—BMP2K—tendon—psoriatic arthritis	0.00233	0.00773	CbGeAlD
Bosutinib—LRRK2—tendon—psoriatic arthritis	0.00231	0.00766	CbGeAlD
Bosutinib—PTK2B—tendon—psoriatic arthritis	0.00225	0.00746	CbGeAlD
Bosutinib—CSNK1E—tendon—psoriatic arthritis	0.00221	0.00734	CbGeAlD
Bosutinib—SIK1—tendon—psoriatic arthritis	0.00218	0.00723	CbGeAlD
Bosutinib—IRAK4—tendon—psoriatic arthritis	0.00218	0.00723	CbGeAlD
Bosutinib—EPHA4—tendon—psoriatic arthritis	0.00215	0.00715	CbGeAlD
Bosutinib—ULK3—tendon—psoriatic arthritis	0.00213	0.00707	CbGeAlD
Bosutinib—MAP2K2—tendon—psoriatic arthritis	0.00213	0.00707	CbGeAlD
Bosutinib—SRC—skin of body—psoriatic arthritis	0.0021	0.00699	CbGeAlD
Bosutinib—MAP3K7—tendon—psoriatic arthritis	0.00209	0.00695	CbGeAlD
Bosutinib—TBK1—tendon—psoriatic arthritis	0.00207	0.00687	CbGeAlD
Bosutinib—PTK2—tendon—psoriatic arthritis	0.00207	0.00687	CbGeAlD
Bosutinib—Acne—Prednisolone—psoriatic arthritis	0.00207	0.0103	CcSEcCtD
Bosutinib—ABCB1—Methylprednisolone—psoriatic arthritis	0.00203	0.167	CbGbCtD
Bosutinib—IRAK1—tendon—psoriatic arthritis	0.00203	0.00674	CbGeAlD
Bosutinib—RPS6KB1—tendon—psoriatic arthritis	0.00199	0.00661	CbGeAlD
Bosutinib—FGR—tendon—psoriatic arthritis	0.00198	0.00657	CbGeAlD
Bosutinib—AXL—tendon—psoriatic arthritis	0.00197	0.00654	CbGeAlD
Bosutinib—Thrombocytopenia—Auranofin—psoriatic arthritis	0.0019	0.00946	CcSEcCtD
Bosutinib—Acne—Triamcinolone—psoriatic arthritis	0.0019	0.00944	CcSEcCtD
Bosutinib—SLK—tendon—psoriatic arthritis	0.0019	0.0063	CbGeAlD
Bosutinib—Acne—Methylprednisolone—psoriatic arthritis	0.0019	0.00942	CcSEcCtD
Bosutinib—CSF1R—skin of body—psoriatic arthritis	0.00189	0.00627	CbGeAlD
Bosutinib—EPHB4—tendon—psoriatic arthritis	0.00188	0.00625	CbGeAlD
Bosutinib—EPHA2—tendon—psoriatic arthritis	0.00185	0.00614	CbGeAlD
Bosutinib—FYN—tendon—psoriatic arthritis	0.00184	0.00612	CbGeAlD
Bosutinib—MAP4K5—tendon—psoriatic arthritis	0.0018	0.00599	CbGeAlD
Bosutinib—MAP3K3—tendon—psoriatic arthritis	0.0018	0.00599	CbGeAlD
Bosutinib—Febrile neutropenia—Methotrexate—psoriatic arthritis	0.00175	0.00872	CcSEcCtD
Bosutinib—Acne—Betamethasone—psoriatic arthritis	0.00172	0.00856	CcSEcCtD
Bosutinib—Acne—Dexamethasone—psoriatic arthritis	0.00172	0.00856	CcSEcCtD
Bosutinib—Decreased appetite—Auranofin—psoriatic arthritis	0.00169	0.0084	CcSEcCtD
Bosutinib—PDGFRB—skin of body—psoriatic arthritis	0.00167	0.00556	CbGeAlD
Bosutinib—YES1—tendon—psoriatic arthritis	0.00166	0.00553	CbGeAlD
Bosutinib—Fluid retention—Prednisolone—psoriatic arthritis	0.00165	0.0082	CcSEcCtD
Bosutinib—STK10—tendon—psoriatic arthritis	0.00165	0.00548	CbGeAlD
Bosutinib—TAOK3—tendon—psoriatic arthritis	0.00164	0.00546	CbGeAlD
Bosutinib—Gastrointestinal pain—Auranofin—psoriatic arthritis	0.00159	0.0079	CcSEcCtD
Bosutinib—Urticaria—Auranofin—psoriatic arthritis	0.00155	0.00768	CcSEcCtD
Bosutinib—Abdominal pain—Auranofin—psoriatic arthritis	0.00154	0.00764	CcSEcCtD
Bosutinib—Fluid retention—Triamcinolone—psoriatic arthritis	0.00152	0.00754	CcSEcCtD
Bosutinib—Fluid retention—Methylprednisolone—psoriatic arthritis	0.00151	0.00752	CcSEcCtD
Bosutinib—Acne—Prednisone—psoriatic arthritis	0.0015	0.00746	CcSEcCtD
Bosutinib—ABL1—skin of body—psoriatic arthritis	0.00149	0.00496	CbGeAlD
Bosutinib—MAP2K5—tendon—psoriatic arthritis	0.00147	0.00489	CbGeAlD
Bosutinib—CSF1R—tendon—psoriatic arthritis	0.00144	0.00477	CbGeAlD
Bosutinib—Pleural effusion—Methotrexate—psoriatic arthritis	0.00138	0.00685	CcSEcCtD
Bosutinib—Fluid retention—Dexamethasone—psoriatic arthritis	0.00138	0.00684	CcSEcCtD
Bosutinib—Fluid retention—Betamethasone—psoriatic arthritis	0.00138	0.00684	CcSEcCtD
Bosutinib—Pruritus—Auranofin—psoriatic arthritis	0.00138	0.00684	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Methylprednisolone—psoriatic arthritis	0.00137	0.0973	CbGdCrCtD
Bosutinib—Hepatotoxicity—Methotrexate—psoriatic arthritis	0.00137	0.00679	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Dexamethasone—psoriatic arthritis	0.00135	0.0957	CbGdCrCtD
Bosutinib—EPHB2—Diflorasone—Betamethasone—psoriatic arthritis	0.00135	0.0957	CbGdCrCtD
Bosutinib—Diarrhoea—Auranofin—psoriatic arthritis	0.00133	0.00661	CcSEcCtD
Bosutinib—ABCB1—Betamethasone—psoriatic arthritis	0.00132	0.108	CbGbCtD
Bosutinib—EPHB2—Diflorasone—Triamcinolone—psoriatic arthritis	0.00132	0.0935	CbGdCrCtD
Bosutinib—ABCB1—Prednisolone—psoriatic arthritis	0.0013	0.107	CbGbCtD
Bosutinib—PDGFRB—tendon—psoriatic arthritis	0.00127	0.00423	CbGeAlD
Bosutinib—EPHB2—Diflorasone—Prednisone—psoriatic arthritis	0.00125	0.0888	CbGdCrCtD
Bosutinib—Vomiting—Auranofin—psoriatic arthritis	0.00124	0.00614	CcSEcCtD
Bosutinib—ABCB1—Prednisone—psoriatic arthritis	0.00123	0.101	CbGbCtD
Bosutinib—Rash—Auranofin—psoriatic arthritis	0.00123	0.00609	CcSEcCtD
Bosutinib—Dermatitis—Auranofin—psoriatic arthritis	0.00123	0.00609	CcSEcCtD
Bosutinib—EPHB2—Diflorasone—Prednisolone—psoriatic arthritis	0.00122	0.0866	CbGdCrCtD
Bosutinib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.00122	0.0999	CbGbCtD
Bosutinib—Fluid retention—Prednisone—psoriatic arthritis	0.0012	0.00596	CcSEcCtD
Bosutinib—Nausea—Auranofin—psoriatic arthritis	0.00116	0.00574	CcSEcCtD
Bosutinib—ABL1—tendon—psoriatic arthritis	0.00114	0.00377	CbGeAlD
Bosutinib—Respiratory failure—Methotrexate—psoriatic arthritis	0.00107	0.00534	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Methylprednisolone—psoriatic arthritis	0.00102	0.00507	CcSEcCtD
Bosutinib—Influenza—Triamcinolone—psoriatic arthritis	0.001	0.00498	CcSEcCtD
Bosutinib—Bronchitis—Triamcinolone—psoriatic arthritis	0.000964	0.00479	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Triamcinolone—psoriatic arthritis	0.000932	0.00463	CcSEcCtD
Bosutinib—CYP3A4—Triamcinolone—psoriatic arthritis	0.000923	0.0757	CbGbCtD
Bosutinib—Gastrointestinal haemorrhage—Prednisone—psoriatic arthritis	0.000917	0.00456	CcSEcCtD
Bosutinib—Infestation—Methylprednisolone—psoriatic arthritis	0.000892	0.00443	CcSEcCtD
Bosutinib—Infestation NOS—Methylprednisolone—psoriatic arthritis	0.000892	0.00443	CcSEcCtD
Bosutinib—Face oedema—Prednisone—psoriatic arthritis	0.000885	0.0044	CcSEcCtD
Bosutinib—Renal failure acute—Methotrexate—psoriatic arthritis	0.00083	0.00412	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Prednisone—psoriatic arthritis	0.000809	0.00402	CcSEcCtD
Bosutinib—CYP3A4—Betamethasone—psoriatic arthritis	0.000792	0.0649	CbGbCtD
Bosutinib—Connective tissue disorder—Methylprednisolone—psoriatic arthritis	0.000787	0.00391	CcSEcCtD
Bosutinib—CYP3A4—Prednisolone—psoriatic arthritis	0.000782	0.0641	CbGbCtD
Bosutinib—ABCB1—Dexamethasone—psoriatic arthritis	0.000769	0.063	CbGbCtD
Bosutinib—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.000743	0.00369	CcSEcCtD
Bosutinib—Neutropenia—Prednisone—psoriatic arthritis	0.000741	0.00368	CcSEcCtD
Bosutinib—CYP3A4—Prednisone—psoriatic arthritis	0.000738	0.0605	CbGbCtD
Bosutinib—Immune system disorder—Methylprednisolone—psoriatic arthritis	0.000723	0.00359	CcSEcCtD
Bosutinib—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.000722	0.00359	CcSEcCtD
Bosutinib—PKMYT1—Danazol—Prednisone—psoriatic arthritis	0.000709	0.0504	CbGdCrCtD
Bosutinib—Ill-defined disorder—Prednisolone—psoriatic arthritis	0.000705	0.0035	CcSEcCtD
Bosutinib—Malnutrition—Methylprednisolone—psoriatic arthritis	0.000697	0.00346	CcSEcCtD
Bosutinib—Malaise—Prednisolone—psoriatic arthritis	0.000685	0.0034	CcSEcCtD
Bosutinib—Dysgeusia—Triamcinolone—psoriatic arthritis	0.000684	0.0034	CcSEcCtD
Bosutinib—CSNK1E—Danazol—Prednisone—psoriatic arthritis	0.000677	0.048	CbGdCrCtD
Bosutinib—Back pain—Triamcinolone—psoriatic arthritis	0.000676	0.00336	CcSEcCtD
Bosutinib—Ill-defined disorder—Triamcinolone—psoriatic arthritis	0.000648	0.00322	CcSEcCtD
Bosutinib—Ill-defined disorder—Methylprednisolone—psoriatic arthritis	0.000647	0.00321	CcSEcCtD
Bosutinib—Discomfort—Prednisolone—psoriatic arthritis	0.000639	0.00318	CcSEcCtD
Bosutinib—Abdominal discomfort—Methotrexate—psoriatic arthritis	0.000635	0.00315	CcSEcCtD
Bosutinib—Malaise—Triamcinolone—psoriatic arthritis	0.00063	0.00313	CcSEcCtD
Bosutinib—Pancytopenia—Methotrexate—psoriatic arthritis	0.000629	0.00313	CcSEcCtD
Bosutinib—Malaise—Methylprednisolone—psoriatic arthritis	0.000629	0.00312	CcSEcCtD
Bosutinib—Connective tissue disorder—Prednisone—psoriatic arthritis	0.000623	0.0031	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.00062	0.00308	CcSEcCtD
Bosutinib—Oedema—Prednisolone—psoriatic arthritis	0.00062	0.00308	CcSEcCtD
Bosutinib—Neutropenia—Methotrexate—psoriatic arthritis	0.000619	0.00308	CcSEcCtD
Bosutinib—ABCB1—Methotrexate—psoriatic arthritis	0.000618	0.0507	CbGbCtD
Bosutinib—Upper respiratory tract infection—Methotrexate—psoriatic arthritis	0.000616	0.00306	CcSEcCtD
Bosutinib—Cough—Triamcinolone—psoriatic arthritis	0.00061	0.00303	CcSEcCtD
Bosutinib—Myalgia—Triamcinolone—psoriatic arthritis	0.000595	0.00296	CcSEcCtD
Bosutinib—Pneumonia—Methotrexate—psoriatic arthritis	0.000594	0.00295	CcSEcCtD
Bosutinib—Myalgia—Methylprednisolone—psoriatic arthritis	0.000594	0.00295	CcSEcCtD
Bosutinib—Arthralgia—Methylprednisolone—psoriatic arthritis	0.000594	0.00295	CcSEcCtD
Bosutinib—Infestation NOS—Methotrexate—psoriatic arthritis	0.00059	0.00293	CcSEcCtD
Bosutinib—Infestation—Methotrexate—psoriatic arthritis	0.00059	0.00293	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000589	0.00293	CcSEcCtD
Bosutinib—Ill-defined disorder—Dexamethasone—psoriatic arthritis	0.000588	0.00292	CcSEcCtD
Bosutinib—Ill-defined disorder—Betamethasone—psoriatic arthritis	0.000588	0.00292	CcSEcCtD
Bosutinib—Discomfort—Triamcinolone—psoriatic arthritis	0.000588	0.00292	CcSEcCtD
Bosutinib—Discomfort—Methylprednisolone—psoriatic arthritis	0.000586	0.00291	CcSEcCtD
Bosutinib—Renal failure—Methotrexate—psoriatic arthritis	0.00058	0.00288	CcSEcCtD
Bosutinib—Immune system disorder—Prednisone—psoriatic arthritis	0.000573	0.00285	CcSEcCtD
Bosutinib—Malaise—Dexamethasone—psoriatic arthritis	0.000572	0.00284	CcSEcCtD
Bosutinib—Malaise—Betamethasone—psoriatic arthritis	0.000572	0.00284	CcSEcCtD
Bosutinib—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.00057	0.00283	CcSEcCtD
Bosutinib—Oedema—Triamcinolone—psoriatic arthritis	0.00057	0.00283	CcSEcCtD
Bosutinib—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.000569	0.00283	CcSEcCtD
Bosutinib—Infection—Triamcinolone—psoriatic arthritis	0.000567	0.00282	CcSEcCtD
Bosutinib—Infection—Methylprednisolone—psoriatic arthritis	0.000565	0.00281	CcSEcCtD
Bosutinib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000558	0.00277	CcSEcCtD
Bosutinib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000558	0.00277	CcSEcCtD
Bosutinib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000553	0.00275	CcSEcCtD
Bosutinib—Malnutrition—Prednisone—psoriatic arthritis	0.000552	0.00274	CcSEcCtD
Bosutinib—Agranulocytosis—Methotrexate—psoriatic arthritis	0.000551	0.00274	CcSEcCtD
Bosutinib—Myalgia—Betamethasone—psoriatic arthritis	0.00054	0.00268	CcSEcCtD
Bosutinib—Myalgia—Dexamethasone—psoriatic arthritis	0.00054	0.00268	CcSEcCtD
Bosutinib—Discomfort—Betamethasone—psoriatic arthritis	0.000533	0.00265	CcSEcCtD
Bosutinib—Discomfort—Dexamethasone—psoriatic arthritis	0.000533	0.00265	CcSEcCtD
Bosutinib—Pain—Prednisolone—psoriatic arthritis	0.00053	0.00264	CcSEcCtD
Bosutinib—Hepatitis—Methotrexate—psoriatic arthritis	0.00053	0.00263	CcSEcCtD
Bosutinib—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000523	0.0026	CcSEcCtD
Bosutinib—Urethral disorder—Methotrexate—psoriatic arthritis	0.00052	0.00258	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.00052	0.00258	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000518	0.00258	CcSEcCtD
Bosutinib—Oedema—Betamethasone—psoriatic arthritis	0.000517	0.00257	CcSEcCtD
Bosutinib—Oedema—Dexamethasone—psoriatic arthritis	0.000517	0.00257	CcSEcCtD
Bosutinib—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000517	0.00257	CcSEcCtD
Bosutinib—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000517	0.00257	CcSEcCtD
Bosutinib—Infection—Betamethasone—psoriatic arthritis	0.000514	0.00255	CcSEcCtD
Bosutinib—Infection—Dexamethasone—psoriatic arthritis	0.000514	0.00255	CcSEcCtD
Bosutinib—Ill-defined disorder—Prednisone—psoriatic arthritis	0.000512	0.00255	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisolone—psoriatic arthritis	0.000511	0.00254	CcSEcCtD
Bosutinib—Anaemia—Prednisone—psoriatic arthritis	0.00051	0.00254	CcSEcCtD
Bosutinib—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000508	0.00253	CcSEcCtD
Bosutinib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000507	0.00252	CcSEcCtD
Bosutinib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000507	0.00252	CcSEcCtD
Bosutinib—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000507	0.00252	CcSEcCtD
Bosutinib—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000507	0.00252	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000501	0.00249	CcSEcCtD
Bosutinib—Malaise—Prednisone—psoriatic arthritis	0.000498	0.00247	CcSEcCtD
Bosutinib—Tinnitus—Methotrexate—psoriatic arthritis	0.000494	0.00246	CcSEcCtD
Bosutinib—Urticaria—Prednisolone—psoriatic arthritis	0.000493	0.00245	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000492	0.00244	CcSEcCtD
Bosutinib—Fatigue—Triamcinolone—psoriatic arthritis	0.000492	0.00244	CcSEcCtD
Bosutinib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000491	0.00244	CcSEcCtD
Bosutinib—Pain—Triamcinolone—psoriatic arthritis	0.000488	0.00242	CcSEcCtD
Bosutinib—Immune system disorder—Methotrexate—psoriatic arthritis	0.000479	0.00238	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000478	0.00237	CcSEcCtD
Bosutinib—CSNK1E—Dexamethasone—Methylprednisolone—psoriatic arthritis	0.000473	0.0336	CbGdCrCtD
Bosutinib—CSNK1E—Betamethasone—Methylprednisolone—psoriatic arthritis	0.000473	0.0336	CbGdCrCtD
Bosutinib—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000471	0.00234	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000471	0.00234	CcSEcCtD
Bosutinib—Myalgia—Prednisone—psoriatic arthritis	0.00047	0.00234	CcSEcCtD
Bosutinib—Arthralgia—Prednisone—psoriatic arthritis	0.00047	0.00234	CcSEcCtD
Bosutinib—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.00047	0.00234	CcSEcCtD
Bosutinib—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.000469	0.00233	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000467	0.00232	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Dexamethasone—psoriatic arthritis	0.000466	0.0331	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Betamethasone—psoriatic arthritis	0.000466	0.0331	CbGdCrCtD
Bosutinib—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000465	0.00231	CcSEcCtD
Bosutinib—Discomfort—Prednisone—psoriatic arthritis	0.000464	0.00231	CcSEcCtD
Bosutinib—Malnutrition—Methotrexate—psoriatic arthritis	0.000461	0.00229	CcSEcCtD
Bosutinib—CYP3A4—Dexamethasone—psoriatic arthritis	0.000461	0.0378	CbGbCtD
Bosutinib—CSNK1E—Betamethasone—Triamcinolone—psoriatic arthritis	0.000455	0.0323	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Triamcinolone—psoriatic arthritis	0.000455	0.0323	CbGdCrCtD
Bosutinib—Urticaria—Triamcinolone—psoriatic arthritis	0.000453	0.00225	CcSEcCtD
Bosutinib—Urticaria—Methylprednisolone—psoriatic arthritis	0.000452	0.00225	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—psoriatic arthritis	0.000452	0.00225	CcSEcCtD
Bosutinib—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000451	0.00224	CcSEcCtD
Bosutinib—Oedema—Prednisone—psoriatic arthritis	0.000451	0.00224	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisone—psoriatic arthritis	0.000451	0.00224	CcSEcCtD
Bosutinib—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.00045	0.00224	CcSEcCtD
Bosutinib—Decreased appetite—Betamethasone—psoriatic arthritis	0.00045	0.00224	CcSEcCtD
Bosutinib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.00045	0.00224	CcSEcCtD
Bosutinib—Infection—Prednisone—psoriatic arthritis	0.000448	0.00222	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000447	0.00222	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000447	0.00222	CcSEcCtD
Bosutinib—Back pain—Methotrexate—psoriatic arthritis	0.000446	0.00222	CcSEcCtD
Bosutinib—Fatigue—Betamethasone—psoriatic arthritis	0.000446	0.00222	CcSEcCtD
Bosutinib—Fatigue—Dexamethasone—psoriatic arthritis	0.000446	0.00222	CcSEcCtD
Bosutinib—Pain—Betamethasone—psoriatic arthritis	0.000442	0.0022	CcSEcCtD
Bosutinib—Pain—Dexamethasone—psoriatic arthritis	0.000442	0.0022	CcSEcCtD
Bosutinib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000442	0.0022	CcSEcCtD
Bosutinib—Skin disorder—Prednisone—psoriatic arthritis	0.000438	0.00217	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Prednisone—psoriatic arthritis	0.000432	0.0307	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisone—psoriatic arthritis	0.000432	0.0307	CbGdCrCtD
Bosutinib—Ill-defined disorder—Methotrexate—psoriatic arthritis	0.000428	0.00213	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—psoriatic arthritis	0.000427	0.00212	CcSEcCtD
Bosutinib—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.000426	0.00212	CcSEcCtD
Bosutinib—Feeling abnormal—Betamethasone—psoriatic arthritis	0.000426	0.00212	CcSEcCtD
Bosutinib—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000423	0.0021	CcSEcCtD
Bosutinib—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000423	0.0021	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Prednisolone—psoriatic arthritis	0.000422	0.0299	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisolone—psoriatic arthritis	0.000422	0.0299	CbGdCrCtD
Bosutinib—Malaise—Methotrexate—psoriatic arthritis	0.000416	0.00207	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—psoriatic arthritis	0.000413	0.00205	CcSEcCtD
Bosutinib—Urticaria—Betamethasone—psoriatic arthritis	0.000411	0.00204	CcSEcCtD
Bosutinib—Urticaria—Dexamethasone—psoriatic arthritis	0.000411	0.00204	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000411	0.00204	CcSEcCtD
Bosutinib—Dizziness—Prednisolone—psoriatic arthritis	0.00041	0.00204	CcSEcCtD
Bosutinib—Asthenia—Triamcinolone—psoriatic arthritis	0.000409	0.00203	CcSEcCtD
Bosutinib—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000409	0.00203	CcSEcCtD
Bosutinib—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000409	0.00203	CcSEcCtD
Bosutinib—Abdominal pain—Betamethasone—psoriatic arthritis	0.000409	0.00203	CcSEcCtD
Bosutinib—Body temperature increased—Betamethasone—psoriatic arthritis	0.000409	0.00203	CcSEcCtD
Bosutinib—Asthenia—Methylprednisolone—psoriatic arthritis	0.000408	0.00203	CcSEcCtD
Bosutinib—Pruritus—Triamcinolone—psoriatic arthritis	0.000403	0.002	CcSEcCtD
Bosutinib—Cough—Methotrexate—psoriatic arthritis	0.000403	0.002	CcSEcCtD
Bosutinib—Pruritus—Methylprednisolone—psoriatic arthritis	0.000403	0.002	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—psoriatic arthritis	0.000393	0.00195	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—psoriatic arthritis	0.000393	0.00195	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—psoriatic arthritis	0.000393	0.00195	CcSEcCtD
Bosutinib—Decreased appetite—Prednisone—psoriatic arthritis	0.000392	0.00195	CcSEcCtD
Bosutinib—Rash—Prednisolone—psoriatic arthritis	0.000391	0.00194	CcSEcCtD
Bosutinib—Dermatitis—Prednisolone—psoriatic arthritis	0.000391	0.00194	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.00039	0.00194	CcSEcCtD
Bosutinib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000389	0.00193	CcSEcCtD
Bosutinib—Fatigue—Prednisone—psoriatic arthritis	0.000389	0.00193	CcSEcCtD
Bosutinib—Headache—Prednisolone—psoriatic arthritis	0.000388	0.00193	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—psoriatic arthritis	0.000388	0.00193	CcSEcCtD
Bosutinib—Dizziness—Triamcinolone—psoriatic arthritis	0.000377	0.00187	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.000377	0.00187	CcSEcCtD
Bosutinib—Dizziness—Methylprednisolone—psoriatic arthritis	0.000376	0.00187	CcSEcCtD
Bosutinib—Infection—Methotrexate—psoriatic arthritis	0.000374	0.00186	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisone—psoriatic arthritis	0.000371	0.00185	CcSEcCtD
Bosutinib—Asthenia—Betamethasone—psoriatic arthritis	0.000371	0.00184	CcSEcCtD
Bosutinib—Asthenia—Dexamethasone—psoriatic arthritis	0.000371	0.00184	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000369	0.00184	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000369	0.00183	CcSEcCtD
Bosutinib—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000368	0.00183	CcSEcCtD
Bosutinib—Nausea—Prednisolone—psoriatic arthritis	0.000368	0.00183	CcSEcCtD
Bosutinib—Pruritus—Betamethasone—psoriatic arthritis	0.000366	0.00182	CcSEcCtD
Bosutinib—Pruritus—Dexamethasone—psoriatic arthritis	0.000366	0.00182	CcSEcCtD
Bosutinib—Skin disorder—Methotrexate—psoriatic arthritis	0.000366	0.00182	CcSEcCtD
Bosutinib—Vomiting—Triamcinolone—psoriatic arthritis	0.000363	0.0018	CcSEcCtD
Bosutinib—Vomiting—Methylprednisolone—psoriatic arthritis	0.000362	0.0018	CcSEcCtD
Bosutinib—Rash—Triamcinolone—psoriatic arthritis	0.00036	0.00179	CcSEcCtD
Bosutinib—Dermatitis—Triamcinolone—psoriatic arthritis	0.000359	0.00179	CcSEcCtD
Bosutinib—Rash—Methylprednisolone—psoriatic arthritis	0.000359	0.00178	CcSEcCtD
Bosutinib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000358	0.00178	CcSEcCtD
Bosutinib—Urticaria—Prednisone—psoriatic arthritis	0.000358	0.00178	CcSEcCtD
Bosutinib—Headache—Triamcinolone—psoriatic arthritis	0.000357	0.00178	CcSEcCtD
Bosutinib—Headache—Methylprednisolone—psoriatic arthritis	0.000356	0.00177	CcSEcCtD
Bosutinib—Body temperature increased—Prednisone—psoriatic arthritis	0.000356	0.00177	CcSEcCtD
Bosutinib—Abdominal pain—Prednisone—psoriatic arthritis	0.000356	0.00177	CcSEcCtD
Bosutinib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000354	0.00176	CcSEcCtD
Bosutinib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000354	0.00176	CcSEcCtD
Bosutinib—CHEK2—Danazol—Prednisone—psoriatic arthritis	0.000346	0.0246	CbGdCrCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000343	0.0017	CcSEcCtD
Bosutinib—Dizziness—Betamethasone—psoriatic arthritis	0.000342	0.0017	CcSEcCtD
Bosutinib—Dizziness—Dexamethasone—psoriatic arthritis	0.000342	0.0017	CcSEcCtD
Bosutinib—Nausea—Triamcinolone—psoriatic arthritis	0.000339	0.00168	CcSEcCtD
Bosutinib—Nausea—Methylprednisolone—psoriatic arthritis	0.000338	0.00168	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—psoriatic arthritis	0.000336	0.00167	CcSEcCtD
Bosutinib—Vomiting—Dexamethasone—psoriatic arthritis	0.000329	0.00163	CcSEcCtD
Bosutinib—Vomiting—Betamethasone—psoriatic arthritis	0.000329	0.00163	CcSEcCtD
Bosutinib—Decreased appetite—Methotrexate—psoriatic arthritis	0.000327	0.00163	CcSEcCtD
Bosutinib—Rash—Dexamethasone—psoriatic arthritis	0.000326	0.00162	CcSEcCtD
Bosutinib—Rash—Betamethasone—psoriatic arthritis	0.000326	0.00162	CcSEcCtD
Bosutinib—Dermatitis—Dexamethasone—psoriatic arthritis	0.000326	0.00162	CcSEcCtD
Bosutinib—Dermatitis—Betamethasone—psoriatic arthritis	0.000326	0.00162	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000325	0.00162	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—psoriatic arthritis	0.000325	0.00161	CcSEcCtD
Bosutinib—Headache—Betamethasone—psoriatic arthritis	0.000324	0.00161	CcSEcCtD
Bosutinib—Headache—Dexamethasone—psoriatic arthritis	0.000324	0.00161	CcSEcCtD
Bosutinib—Asthenia—Prednisone—psoriatic arthritis	0.000323	0.00161	CcSEcCtD
Bosutinib—Pain—Methotrexate—psoriatic arthritis	0.000322	0.0016	CcSEcCtD
Bosutinib—Pruritus—Prednisone—psoriatic arthritis	0.000319	0.00158	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—psoriatic arthritis	0.00031	0.00154	CcSEcCtD
Bosutinib—Diarrhoea—Prednisone—psoriatic arthritis	0.000308	0.00153	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000308	0.00153	CcSEcCtD
Bosutinib—Nausea—Dexamethasone—psoriatic arthritis	0.000307	0.00153	CcSEcCtD
Bosutinib—Nausea—Betamethasone—psoriatic arthritis	0.000307	0.00153	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—psoriatic arthritis	0.000299	0.00149	CcSEcCtD
Bosutinib—Dizziness—Prednisone—psoriatic arthritis	0.000298	0.00148	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—psoriatic arthritis	0.000298	0.00148	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—psoriatic arthritis	0.000298	0.00148	CcSEcCtD
Bosutinib—Vomiting—Prednisone—psoriatic arthritis	0.000287	0.00142	CcSEcCtD
Bosutinib—Rash—Prednisone—psoriatic arthritis	0.000284	0.00141	CcSEcCtD
Bosutinib—Dermatitis—Prednisone—psoriatic arthritis	0.000284	0.00141	CcSEcCtD
Bosutinib—Headache—Prednisone—psoriatic arthritis	0.000282	0.0014	CcSEcCtD
Bosutinib—Asthenia—Methotrexate—psoriatic arthritis	0.00027	0.00134	CcSEcCtD
Bosutinib—Nausea—Prednisone—psoriatic arthritis	0.000268	0.00133	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—psoriatic arthritis	0.000266	0.00132	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—psoriatic arthritis	0.000258	0.00128	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—psoriatic arthritis	0.000249	0.00124	CcSEcCtD
Bosutinib—Vomiting—Methotrexate—psoriatic arthritis	0.000239	0.00119	CcSEcCtD
Bosutinib—Rash—Methotrexate—psoriatic arthritis	0.000237	0.00118	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—psoriatic arthritis	0.000237	0.00118	CcSEcCtD
Bosutinib—Headache—Methotrexate—psoriatic arthritis	0.000236	0.00117	CcSEcCtD
Bosutinib—Nausea—Methotrexate—psoriatic arthritis	0.000224	0.00111	CcSEcCtD
Bosutinib—LCK—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000134	0.000284	CbGpPWpGaD
Bosutinib—PTK2—Immune System—REL—psoriatic arthritis	0.000133	0.000282	CbGpPWpGaD
Bosutinib—BTK—Immune System—NOD2—psoriatic arthritis	0.000133	0.000282	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—REL—psoriatic arthritis	0.000132	0.000281	CbGpPWpGaD
Bosutinib—PRKCQ—Immune System—HLA-B—psoriatic arthritis	0.000132	0.000281	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—HLA-C—psoriatic arthritis	0.000132	0.000279	CbGpPWpGaD
Bosutinib—YES1—Immune System—REL—psoriatic arthritis	0.000131	0.000279	CbGpPWpGaD
Bosutinib—EPHB3—Developmental Biology—TNF—psoriatic arthritis	0.000131	0.000278	CbGpPWpGaD
Bosutinib—IKBKE—Immune System—HLA-DRB1—psoriatic arthritis	0.000131	0.000277	CbGpPWpGaD
Bosutinib—ERBB4—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000129	0.000273	CbGpPWpGaD
Bosutinib—CSK—Immune System—HLA-B—psoriatic arthritis	0.000128	0.000271	CbGpPWpGaD
Bosutinib—SRC—Immune System—MEFV—psoriatic arthritis	0.000128	0.000271	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—NOD2—psoriatic arthritis	0.000127	0.000269	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—HLA-C—psoriatic arthritis	0.000127	0.000269	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000126	0.000268	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—REL—psoriatic arthritis	0.000125	0.000264	CbGpPWpGaD
Bosutinib—PTK2—Innate Immune System—HLA-B—psoriatic arthritis	0.000124	0.000264	CbGpPWpGaD
Bosutinib—BLK—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000124	0.000263	CbGpPWpGaD
Bosutinib—ERBB3—Innate Immune System—CRP—psoriatic arthritis	0.000124	0.000262	CbGpPWpGaD
Bosutinib—FES—Developmental Biology—TNF—psoriatic arthritis	0.000123	0.000262	CbGpPWpGaD
Bosutinib—YES1—Innate Immune System—HLA-B—psoriatic arthritis	0.000123	0.00026	CbGpPWpGaD
Bosutinib—PTK2—Immune System—HLA-C—psoriatic arthritis	0.000123	0.00026	CbGpPWpGaD
Bosutinib—HCK—Immune System—NOD2—psoriatic arthritis	0.000122	0.000259	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000122	0.000258	CbGpPWpGaD
Bosutinib—YES1—Immune System—HLA-C—psoriatic arthritis	0.000121	0.000256	CbGpPWpGaD
Bosutinib—MAP2K2—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.00012	0.000254	CbGpPWpGaD
Bosutinib—SYK—Immune System—CRP—psoriatic arthritis	0.000119	0.000253	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—NOD2—psoriatic arthritis	0.000119	0.000253	CbGpPWpGaD
Bosutinib—YES1—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000118	0.00025	CbGpPWpGaD
Bosutinib—MAP3K7—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000118	0.00025	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—REL—psoriatic arthritis	0.000117	0.000249	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—REL—psoriatic arthritis	0.000117	0.000249	CbGpPWpGaD
Bosutinib—PRKCQ—Immune System—CRP—psoriatic arthritis	0.000117	0.000248	CbGpPWpGaD
Bosutinib—EPHA3—Developmental Biology—TNF—psoriatic arthritis	0.000117	0.000248	CbGpPWpGaD
Bosutinib—EPHA5—Developmental Biology—TNF—psoriatic arthritis	0.000117	0.000248	CbGpPWpGaD
Bosutinib—ABL2—Developmental Biology—TNF—psoriatic arthritis	0.000117	0.000248	CbGpPWpGaD
Bosutinib—IRAK1—Innate Immune System—HLA-B—psoriatic arthritis	0.000116	0.000247	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—NOD2—psoriatic arthritis	0.000116	0.000247	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—NOD2—psoriatic arthritis	0.000115	0.000244	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—HLA-C—psoriatic arthritis	0.000115	0.000243	CbGpPWpGaD
Bosutinib—TBK1—Immune System—HLA-B—psoriatic arthritis	0.000115	0.000243	CbGpPWpGaD
Bosutinib—SYK—Immune System—HLA-DRB1—psoriatic arthritis	0.000114	0.000242	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—NOD2—psoriatic arthritis	0.000114	0.000241	CbGpPWpGaD
Bosutinib—ERBB3—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000114	0.000241	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—NOD2—psoriatic arthritis	0.000113	0.00024	CbGpPWpGaD
Bosutinib—LCK—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000113	0.00024	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—NOD2—psoriatic arthritis	0.000113	0.00024	CbGpPWpGaD
Bosutinib—CSK—Immune System—CRP—psoriatic arthritis	0.000113	0.00024	CbGpPWpGaD
Bosutinib—EPHA8—Developmental Biology—TNF—psoriatic arthritis	0.000113	0.000239	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—HLA-B—psoriatic arthritis	0.000112	0.000239	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—HLA-C—psoriatic arthritis	0.000112	0.000238	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—NOD2—psoriatic arthritis	0.000112	0.000238	CbGpPWpGaD
Bosutinib—PRKCQ—Immune System—HLA-DRB1—psoriatic arthritis	0.000112	0.000238	CbGpPWpGaD
Bosutinib—MAP2K1—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000112	0.000237	CbGpPWpGaD
Bosutinib—EPHA4—Developmental Biology—TNF—psoriatic arthritis	0.000111	0.000237	CbGpPWpGaD
Bosutinib—EPHB4—Developmental Biology—TNF—psoriatic arthritis	0.000111	0.000237	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—NOD2—psoriatic arthritis	0.000111	0.000236	CbGpPWpGaD
Bosutinib—PTK2—Hemostasis—NOS2—psoriatic arthritis	0.000111	0.000236	CbGpPWpGaD
Bosutinib—EGFR—Spinal Cord Injury—TNF—psoriatic arthritis	0.000111	0.000235	CbGpPWpGaD
Bosutinib—BLK—Immune System—NOD2—psoriatic arthritis	0.00011	0.000234	CbGpPWpGaD
Bosutinib—FGR—Immune System—NOD2—psoriatic arthritis	0.00011	0.000234	CbGpPWpGaD
Bosutinib—PTK2—Innate Immune System—CRP—psoriatic arthritis	0.00011	0.000233	CbGpPWpGaD
Bosutinib—YES1—Hemostasis—NOS2—psoriatic arthritis	0.00011	0.000233	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—HLA-B—psoriatic arthritis	0.00011	0.000233	CbGpPWpGaD
Bosutinib—MAP3K7—Innate Immune System—HLA-B—psoriatic arthritis	0.00011	0.000232	CbGpPWpGaD
Bosutinib—YES1—Innate Immune System—CRP—psoriatic arthritis	0.000108	0.00023	CbGpPWpGaD
Bosutinib—CSK—Immune System—HLA-DRB1—psoriatic arthritis	0.000108	0.000229	CbGpPWpGaD
Bosutinib—EPHB2—Developmental Biology—TNF—psoriatic arthritis	0.000108	0.000229	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—HLA-C—psoriatic arthritis	0.000108	0.000229	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000108	0.000229	CbGpPWpGaD
Bosutinib—BTK—Immune System—HLA-B—psoriatic arthritis	0.000107	0.000227	CbGpPWpGaD
Bosutinib—MAP3K7—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000105	0.000223	CbGpPWpGaD
Bosutinib—PRKCQ—Developmental Biology—TNF—psoriatic arthritis	0.000103	0.000218	CbGpPWpGaD
Bosutinib—IRAK1—Innate Immune System—CRP—psoriatic arthritis	0.000103	0.000218	CbGpPWpGaD
Bosutinib—MAP2K2—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000103	0.000218	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—REL—psoriatic arthritis	0.000102	0.000217	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—HLA-B—psoriatic arthritis	0.000102	0.000217	CbGpPWpGaD
Bosutinib—TBK1—Immune System—CRP—psoriatic arthritis	0.000101	0.000215	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—NOD2—psoriatic arthritis	0.000101	0.000215	CbGpPWpGaD
Bosutinib—PDGFRB—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.0001	0.000213	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—REL—psoriatic arthritis	0.0001	0.000212	CbGpPWpGaD
Bosutinib—YES1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	9.97e-05	0.000212	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—CRP—psoriatic arthritis	9.94e-05	0.000211	CbGpPWpGaD
Bosutinib—PRKCQ—Disease—NOS2—psoriatic arthritis	9.84e-05	0.000209	CbGpPWpGaD
Bosutinib—CSNK1A1—Disease—NOS2—psoriatic arthritis	9.84e-05	0.000209	CbGpPWpGaD
Bosutinib—HCK—Immune System—HLA-B—psoriatic arthritis	9.81e-05	0.000208	CbGpPWpGaD
Bosutinib—LYN—Immune System—REL—psoriatic arthritis	9.79e-05	0.000208	CbGpPWpGaD
Bosutinib—ABL1—Immune System—REL—psoriatic arthritis	9.75e-05	0.000207	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—CRP—psoriatic arthritis	9.71e-05	0.000206	CbGpPWpGaD
Bosutinib—TBK1—Immune System—HLA-DRB1—psoriatic arthritis	9.7e-05	0.000206	CbGpPWpGaD
Bosutinib—MAP3K7—Innate Immune System—CRP—psoriatic arthritis	9.69e-05	0.000205	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—NOD2—psoriatic arthritis	9.68e-05	0.000205	CbGpPWpGaD
Bosutinib—FYN—Immune System—REL—psoriatic arthritis	9.64e-05	0.000205	CbGpPWpGaD
Bosutinib—MAP2K1—MAPK Signaling Pathway—TNF—psoriatic arthritis	9.62e-05	0.000204	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—REL—psoriatic arthritis	9.59e-05	0.000203	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—HLA-B—psoriatic arthritis	9.58e-05	0.000203	CbGpPWpGaD
Bosutinib—CAMK2G—Immune System—HLA-DRB1—psoriatic arthritis	9.52e-05	0.000202	CbGpPWpGaD
Bosutinib—CSK—Disease—NOS2—psoriatic arthritis	9.51e-05	0.000202	CbGpPWpGaD
Bosutinib—BTK—Immune System—CRP—psoriatic arthritis	9.45e-05	0.0002	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HLA-C—psoriatic arthritis	9.43e-05	0.0002	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—HLA-B—psoriatic arthritis	9.35e-05	0.000198	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—NOD2—psoriatic arthritis	9.33e-05	0.000198	CbGpPWpGaD
Bosutinib—MAP3K3—Immune System—HLA-DRB1—psoriatic arthritis	9.3e-05	0.000197	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—HLA-B—psoriatic arthritis	9.24e-05	0.000196	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HLA-C—psoriatic arthritis	9.2e-05	0.000195	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—HLA-B—psoriatic arthritis	9.15e-05	0.000194	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—HLA-B—psoriatic arthritis	9.11e-05	0.000193	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—HLA-B—psoriatic arthritis	9.1e-05	0.000193	CbGpPWpGaD
Bosutinib—EPHA2—Developmental Biology—TNF—psoriatic arthritis	9.09e-05	0.000193	CbGpPWpGaD
Bosutinib—BTK—Immune System—HLA-DRB1—psoriatic arthritis	9.05e-05	0.000192	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—CRP—psoriatic arthritis	9.03e-05	0.000191	CbGpPWpGaD
Bosutinib—PTK2—Immune System—NOD2—psoriatic arthritis	9.01e-05	0.000191	CbGpPWpGaD
Bosutinib—LYN—Immune System—HLA-C—psoriatic arthritis	9.01e-05	0.000191	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—HLA-B—psoriatic arthritis	9.01e-05	0.000191	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—HLA-B—psoriatic arthritis	8.97e-05	0.00019	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HLA-C—psoriatic arthritis	8.97e-05	0.00019	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—HLA-B—psoriatic arthritis	8.96e-05	0.00019	CbGpPWpGaD
Bosutinib—MAP3K7—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	8.91e-05	0.000189	CbGpPWpGaD
Bosutinib—YES1—Immune System—NOD2—psoriatic arthritis	8.89e-05	0.000189	CbGpPWpGaD
Bosutinib—BLK—Immune System—HLA-B—psoriatic arthritis	8.88e-05	0.000188	CbGpPWpGaD
Bosutinib—FYN—Immune System—HLA-C—psoriatic arthritis	8.87e-05	0.000188	CbGpPWpGaD
Bosutinib—FGR—Immune System—HLA-B—psoriatic arthritis	8.85e-05	0.000188	CbGpPWpGaD
Bosutinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	8.83e-05	0.000187	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HLA-C—psoriatic arthritis	8.83e-05	0.000187	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—HLA-B—psoriatic arthritis	8.79e-05	0.000186	CbGpPWpGaD
Bosutinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	8.68e-05	0.000184	CbGpPWpGaD
Bosutinib—HCK—Immune System—CRP—psoriatic arthritis	8.67e-05	0.000184	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—HLA-B—psoriatic arthritis	8.65e-05	0.000183	CbGpPWpGaD
Bosutinib—IRAK4—Immune System—HLA-DRB1—psoriatic arthritis	8.64e-05	0.000183	CbGpPWpGaD
Bosutinib—MAP2K2—Innate Immune System—CRP—psoriatic arthritis	8.47e-05	0.00018	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—NOD2—psoriatic arthritis	8.43e-05	0.000179	CbGpPWpGaD
Bosutinib—EGFR—MAPK Signaling Pathway—TNF—psoriatic arthritis	8.36e-05	0.000177	CbGpPWpGaD
Bosutinib—EGFR—Immune System—REL—psoriatic arthritis	8.33e-05	0.000177	CbGpPWpGaD
Bosutinib—HCK—Immune System—HLA-DRB1—psoriatic arthritis	8.3e-05	0.000176	CbGpPWpGaD
Bosutinib—PDGFRB—Innate Immune System—CRP—psoriatic arthritis	8.26e-05	0.000175	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—NOD2—psoriatic arthritis	8.26e-05	0.000175	CbGpPWpGaD
Bosutinib—LYN—Hemostasis—NOS2—psoriatic arthritis	8.19e-05	0.000174	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—CRP—psoriatic arthritis	8.16e-05	0.000173	CbGpPWpGaD
Bosutinib—ABL1—Hemostasis—NOS2—psoriatic arthritis	8.15e-05	0.000173	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—HLA-B—psoriatic arthritis	8.14e-05	0.000173	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—CRP—psoriatic arthritis	8.09e-05	0.000172	CbGpPWpGaD
Bosutinib—FYN—Hemostasis—NOS2—psoriatic arthritis	8.07e-05	0.000171	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—CRP—psoriatic arthritis	8.05e-05	0.000171	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—CRP—psoriatic arthritis	8.05e-05	0.000171	CbGpPWpGaD
Bosutinib—LCK—Immune System—REL—psoriatic arthritis	8.03e-05	0.00017	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—CRP—psoriatic arthritis	7.96e-05	0.000169	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—NOS2—psoriatic arthritis	7.95e-05	0.000169	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—NOD2—psoriatic arthritis	7.94e-05	0.000168	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—CRP—psoriatic arthritis	7.92e-05	0.000168	CbGpPWpGaD
Bosutinib—BLK—Immune System—CRP—psoriatic arthritis	7.85e-05	0.000167	CbGpPWpGaD
Bosutinib—FGR—Immune System—CRP—psoriatic arthritis	7.83e-05	0.000166	CbGpPWpGaD
Bosutinib—ERBB4—Immune System—HLA-DRB1—psoriatic arthritis	7.82e-05	0.000166	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—HLA-B—psoriatic arthritis	7.78e-05	0.000165	CbGpPWpGaD
Bosutinib—ABCB1—Allograft Rejection—TNF—psoriatic arthritis	7.71e-05	0.000164	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—HLA-DRB1—psoriatic arthritis	7.71e-05	0.000163	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HLA-C—psoriatic arthritis	7.67e-05	0.000163	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	7.6e-05	0.000161	CbGpPWpGaD
Bosutinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	7.54e-05	0.00016	CbGpPWpGaD
Bosutinib—BLK—Immune System—HLA-DRB1—psoriatic arthritis	7.52e-05	0.00016	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—HLA-B—psoriatic arthritis	7.5e-05	0.000159	CbGpPWpGaD
Bosutinib—FGR—Immune System—HLA-DRB1—psoriatic arthritis	7.5e-05	0.000159	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—HLA-B—psoriatic arthritis	7.47e-05	0.000159	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	7.44e-05	0.000158	CbGpPWpGaD
Bosutinib—LCK—Immune System—HLA-C—psoriatic arthritis	7.39e-05	0.000157	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	7.32e-05	0.000155	CbGpPWpGaD
Bosutinib—HCK—Disease—NOS2—psoriatic arthritis	7.3e-05	0.000155	CbGpPWpGaD
Bosutinib—PTK2—Immune System—HLA-B—psoriatic arthritis	7.25e-05	0.000154	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—HLA-B—psoriatic arthritis	7.2e-05	0.000153	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—CRP—psoriatic arthritis	7.2e-05	0.000153	CbGpPWpGaD
Bosutinib—YES1—Immune System—HLA-B—psoriatic arthritis	7.15e-05	0.000152	CbGpPWpGaD
Bosutinib—SRC—Immune System—REL—psoriatic arthritis	7.11e-05	0.000151	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—NOD2—psoriatic arthritis	6.94e-05	0.000147	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—HLA-DRB1—psoriatic arthritis	6.89e-05	0.000146	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—CRP—psoriatic arthritis	6.88e-05	0.000146	CbGpPWpGaD
Bosutinib—ERBB4—Disease—NOS2—psoriatic arthritis	6.87e-05	0.000146	CbGpPWpGaD
Bosutinib—ROCK1—Developmental Biology—TNF—psoriatic arthritis	6.82e-05	0.000145	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—HLA-B—psoriatic arthritis	6.78e-05	0.000144	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—NOD2—psoriatic arthritis	6.77e-05	0.000144	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—NOS2—psoriatic arthritis	6.72e-05	0.000142	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—HLA-B—psoriatic arthritis	6.64e-05	0.000141	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—CRP—psoriatic arthritis	6.63e-05	0.000141	CbGpPWpGaD
Bosutinib—LYN—Immune System—NOD2—psoriatic arthritis	6.63e-05	0.000141	CbGpPWpGaD
Bosutinib—ABL1—Immune System—NOD2—psoriatic arthritis	6.6e-05	0.00014	CbGpPWpGaD
Bosutinib—SRC—Immune System—HLA-C—psoriatic arthritis	6.54e-05	0.000139	CbGpPWpGaD
Bosutinib—FYN—Immune System—NOD2—psoriatic arthritis	6.52e-05	0.000138	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—NOD2—psoriatic arthritis	6.49e-05	0.000138	CbGpPWpGaD
Bosutinib—SRC—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	6.43e-05	0.000136	CbGpPWpGaD
Bosutinib—PTK2—Immune System—CRP—psoriatic arthritis	6.41e-05	0.000136	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—HLA-B—psoriatic arthritis	6.38e-05	0.000135	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—HLA-B—psoriatic arthritis	6.38e-05	0.000135	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	6.33e-05	0.000134	CbGpPWpGaD
Bosutinib—YES1—Immune System—CRP—psoriatic arthritis	6.32e-05	0.000134	CbGpPWpGaD
Bosutinib—PTK2—Immune System—HLA-DRB1—psoriatic arthritis	6.13e-05	0.00013	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	6.1e-05	0.000129	CbGpPWpGaD
Bosutinib—ERBB3—Disease—NOS2—psoriatic arthritis	6.06e-05	0.000129	CbGpPWpGaD
Bosutinib—YES1—Immune System—HLA-DRB1—psoriatic arthritis	6.05e-05	0.000128	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—CRP—psoriatic arthritis	5.99e-05	0.000127	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—NOS2—psoriatic arthritis	5.94e-05	0.000126	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—CRP—psoriatic arthritis	5.87e-05	0.000124	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—HLA-DRB1—psoriatic arthritis	5.74e-05	0.000122	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—CRP—psoriatic arthritis	5.64e-05	0.00012	CbGpPWpGaD
Bosutinib—PTK2—Developmental Biology—TNF—psoriatic arthritis	5.64e-05	0.00012	CbGpPWpGaD
Bosutinib—EGFR—Immune System—NOD2—psoriatic arthritis	5.64e-05	0.00012	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HLA-B—psoriatic arthritis	5.58e-05	0.000118	CbGpPWpGaD
Bosutinib—YES1—Developmental Biology—TNF—psoriatic arthritis	5.56e-05	0.000118	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HLA-B—psoriatic arthritis	5.44e-05	0.000115	CbGpPWpGaD
Bosutinib—LCK—Immune System—NOD2—psoriatic arthritis	5.43e-05	0.000115	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—HLA-DRB1—psoriatic arthritis	5.4e-05	0.000115	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	5.4e-05	0.000114	CbGpPWpGaD
Bosutinib—LYN—Immune System—HLA-B—psoriatic arthritis	5.33e-05	0.000113	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HLA-B—psoriatic arthritis	5.3e-05	0.000113	CbGpPWpGaD
Bosutinib—FYN—Immune System—HLA-B—psoriatic arthritis	5.25e-05	0.000111	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HLA-B—psoriatic arthritis	5.22e-05	0.000111	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—CRP—psoriatic arthritis	4.93e-05	0.000105	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—CRP—psoriatic arthritis	4.81e-05	0.000102	CbGpPWpGaD
Bosutinib—SRC—Immune System—NOD2—psoriatic arthritis	4.81e-05	0.000102	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HLA-DRB1—psoriatic arthritis	4.72e-05	0.0001	CbGpPWpGaD
Bosutinib—LYN—Immune System—CRP—psoriatic arthritis	4.71e-05	9.99e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—CRP—psoriatic arthritis	4.69e-05	9.95e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—CRP—psoriatic arthritis	4.64e-05	9.84e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—CRP—psoriatic arthritis	4.61e-05	9.79e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HLA-DRB1—psoriatic arthritis	4.61e-05	9.77e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HLA-B—psoriatic arthritis	4.53e-05	9.62e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—HLA-DRB1—psoriatic arthritis	4.51e-05	9.57e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HLA-DRB1—psoriatic arthritis	4.49e-05	9.53e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—HLA-DRB1—psoriatic arthritis	4.44e-05	9.42e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HLA-DRB1—psoriatic arthritis	4.42e-05	9.37e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—HLA-B—psoriatic arthritis	4.37e-05	9.27e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Developmental Biology—TNF—psoriatic arthritis	4.34e-05	9.2e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—NOS2—psoriatic arthritis	4.15e-05	8.81e-05	CbGpPWpGaD
Bosutinib—LYN—Developmental Biology—TNF—psoriatic arthritis	4.15e-05	8.79e-05	CbGpPWpGaD
Bosutinib—ABL1—Developmental Biology—TNF—psoriatic arthritis	4.13e-05	8.75e-05	CbGpPWpGaD
Bosutinib—FYN—Developmental Biology—TNF—psoriatic arthritis	4.08e-05	8.66e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Developmental Biology—TNF—psoriatic arthritis	4.06e-05	8.61e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—NOS2—psoriatic arthritis	4.05e-05	8.59e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—CRP—psoriatic arthritis	4.01e-05	8.5e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—NOS2—psoriatic arthritis	3.9e-05	8.28e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—NOS2—psoriatic arthritis	3.88e-05	8.24e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—HLA-B—psoriatic arthritis	3.87e-05	8.2e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—CRP—psoriatic arthritis	3.86e-05	8.19e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HLA-DRB1—psoriatic arthritis	3.84e-05	8.14e-05	CbGpPWpGaD
Bosutinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	3.81e-05	8.07e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—HLA-DRB1—psoriatic arthritis	3.7e-05	7.84e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—TNF—psoriatic arthritis	3.53e-05	7.48e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—CRP—psoriatic arthritis	3.42e-05	7.25e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—NOS2—psoriatic arthritis	3.37e-05	7.16e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—HLA-DRB1—psoriatic arthritis	3.27e-05	6.94e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—NOS2—psoriatic arthritis	3.25e-05	6.9e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—TNF—psoriatic arthritis	3.01e-05	6.38e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—NOS2—psoriatic arthritis	2.88e-05	6.11e-05	CbGpPWpGaD
